148 related articles for article (PubMed ID: 37017812)
41. Correlation of HER2 overexpression with gene amplification and its relation to chromosome 17 aneuploidy: a 5-year experience with invasive ductal and lobular carcinomas.
Nassar A; Khoor A; Radhakrishnan R; Radhakrishnan A; Cohen C
Int J Clin Exp Pathol; 2014; 7(9):6254-61. PubMed ID: 25337277
[TBL] [Abstract][Full Text] [Related]
42. Axillary lymph node status and invasive lobular breast cancer : Analysis of the Clinical Tumor Register of the AGO Austria.
Danzinger S; Pöckl K; Kronawetter G; Pfeifer C; Behrendt S; Gscheidlinger P; Harrasser L; Mühlböck H; Dirschlmayer W; Schauer C; Reitsamer R; Uher H; Schönau K; Delmarko I; Singer CF
Wien Klin Wochenschr; 2023 Sep; 135(17-18):463-471. PubMed ID: 37010596
[TBL] [Abstract][Full Text] [Related]
43. Population-based Study of Prosigna-PAM50 and Outcome Among Postmenopausal Women With Estrogen Receptor-positive and HER2-negative Operable Invasive Lobular or Ductal Breast Cancer.
Lænkholm AV; Jensen MB; Eriksen JO; Roslind A; Buckingham W; Ferree S; Nielsen T; Ejlertsen B
Clin Breast Cancer; 2020 Aug; 20(4):e423-e432. PubMed ID: 32253134
[TBL] [Abstract][Full Text] [Related]
44. Impact of Neoadjuvant Chemotherapy on Breast Cancer Subtype: Does Subtype Change and, if so, How? : IHC Profile and Neoadjuvant Chemotherapy.
De La Cruz LM; Harhay MO; Zhang P; Ugras S
Ann Surg Oncol; 2018 Nov; 25(12):3535-3540. PubMed ID: 29981025
[TBL] [Abstract][Full Text] [Related]
45. Prognostic Value of Coexisting Lobular Carcinoma In Situ With Invasive Lobular Carcinoma.
Harbhajanka A; Lamzabi I; Syed S; Jain R; Ghai R; Reddy VB; Bitterman P; Gattuso P
Appl Immunohistochem Mol Morphol; 2016; 24(10):738-743. PubMed ID: 26574630
[TBL] [Abstract][Full Text] [Related]
46. Clinical characteristics and treatment outcomes of invasive ductal and lobular carcinoma: analyses of 54,832 taiwan cancer registry index cases.
Chen BF; Tsai YF; Lien PJ; Lin YS; Feng CJ; Chen YJ; Cheng HF; Tseng LM; Huang CC
Breast Cancer Res Treat; 2023 Oct; 201(3):547-560. PubMed ID: 37470893
[TBL] [Abstract][Full Text] [Related]
47. The estrogen receptor coactivator AIB1 is a new putative prognostic biomarker in ER-positive/HER2-negative invasive lobular carcinoma of the breast.
Narbe U; Sjöström M; Forsare C; Bendahl PO; Alkner S; Leeb-Lundberg LMF; Lövgren K; Rydén L; Ingvar C; Fernö M
Breast Cancer Res Treat; 2019 Jun; 175(2):305-316. PubMed ID: 30796653
[TBL] [Abstract][Full Text] [Related]
48. Prognostic significance of preoperative
Higuchi T; Nishimukai A; Ozawa H; Fujimoto Y; Yanai A; Miyagawa Y; Murase K; Imamura M; Takatsuka Y; Kitajima K; Fukushima K; Miyoshi Y
Breast; 2016 Dec; 30():5-12. PubMed ID: 27569020
[TBL] [Abstract][Full Text] [Related]
49. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
[TBL] [Abstract][Full Text] [Related]
50. Clinical outcomes using accelerated partial breast irradiation in patients with invasive lobular carcinoma.
Shah C; Wilkinson JB; Shaitelman S; Grills I; Wallace M; Mitchell C; Vicini F
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e547-51. PubMed ID: 21640491
[TBL] [Abstract][Full Text] [Related]
51. Clinicopathological features of and neoadjuvant therapy for human epidermal growth factor receptor 2-positive classic invasive lobular carcinoma.
Huang X; Chen H; Ding Q; Robinson MK; Moseley TW; Bassett RL; Tang G; Lim B; Sahin AA
Hum Pathol; 2021 Nov; 117():51-59. PubMed ID: 34363799
[TBL] [Abstract][Full Text] [Related]
52. Efficacy of chemotherapy in patients with HR+/HER2-Invasive lobular breast cancer.
Yaghi M; Bilani N; Dominguez B; Zerdan MB; Li H; Saravia D; Stone E; Nahleh Z
Cancer Treat Res Commun; 2023; 34():100666. PubMed ID: 36525755
[TBL] [Abstract][Full Text] [Related]
53. Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence.
Brown TA; Mittendorf EA; Hale DF; Myers JW; Peace KM; Jackson DO; Greene JM; Vreeland TJ; Clifton GT; Ardavanis A; Litton JK; Shumway NM; Symanowski J; Murray JL; Ponniah S; Anastasopoulou EA; Pistamaltzian NF; Baxevanis CN; Perez SA; Papamichail M; Peoples GE
Breast Cancer Res Treat; 2020 Jun; 181(2):391-401. PubMed ID: 32323103
[TBL] [Abstract][Full Text] [Related]
54. The Yale University experience of early-stage invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC) treated with breast conservation treatment (BCT): analysis of clinical-pathologic features, long-term outcomes, and molecular expression of COX-2, Bcl-2, and p53 as a function of histology.
Moran MS; Yang Q; Haffty BG
Breast J; 2009; 15(6):571-8. PubMed ID: 19995377
[TBL] [Abstract][Full Text] [Related]
55. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
56. Lack of CD151/integrin α3β1 complex is predictive of poor outcome in node-negative lobular breast carcinoma: opposing roles of CD151 in invasive lobular and ductal breast cancers.
Romanska HM; Potemski P; Krakowska M; Mieszkowska M; Chaudhri S; Kordek R; Kubiak R; Speirs V; Hanby AM; Sadej R; Berditchevski F
Br J Cancer; 2015 Nov; 113(9):1350-7. PubMed ID: 26418423
[TBL] [Abstract][Full Text] [Related]
57. Tumor-infiltrating lymphocytes are associated with poor prognosis in invasive lobular breast carcinoma.
Tille JC; Vieira AF; Saint-Martin C; Djerroudi L; Furhmann L; Bidard FC; Kirova Y; Tardivon A; Reyal F; Carton M; Vincent-Salomon A
Mod Pathol; 2020 Nov; 33(11):2198-2207. PubMed ID: 32404955
[TBL] [Abstract][Full Text] [Related]
58. Adjuvant chemotherapy could not bring survival benefit to HR-positive, HER2-negative, pT1b-c/N0-1/M0 invasive lobular carcinoma of the breast: a propensity score matching study based on SEER database.
Hu G; Hu G; Zhang C; Lin X; Shan M; Yu Y; Lu Y; Niu R; Ye H; Wang C; Xu C
BMC Cancer; 2020 Feb; 20(1):136. PubMed ID: 32085753
[TBL] [Abstract][Full Text] [Related]
59. The role of immunohistochemistry in breast cancer patients treated with neoadjuvant chemotherapy: an old tool with an enduring prognostic value.
Sánchez-Muñoz A; Plata-Fernández YM; Fernández M; Jaén-Morago A; Fernández-Navarro M; de la Torre-Cabrera C; Ramirez-Tortosa C; Lomas-Garrido M; Llácer C; Navarro-Perez V; Alba-Conejo E; Sánchez-Rovira P
Clin Breast Cancer; 2013 Apr; 13(2):146-52. PubMed ID: 23318089
[TBL] [Abstract][Full Text] [Related]
60. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
